PharVision Advisers’s Patterson-UTI PTEN Stock Holding History

PharVision Advisers’s Portfolio PTEN Stock Details PTEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-31,193	Closed	-$191K	–	520
2025 Q4	$191K	Buy	31,193 +367	+1%	+$2.19K	0.1%	579
2025 Q3	$160K	Buy	+30,826	New	+$177K	0.09%	558

Other funds holding PTEN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

PharVision Advisers's PTEN Position: Q1 2026 in Review

PharVision Advisers sold out of Patterson-UTI (PTEN) in Q1 2026, closing a stake of 31,193 shares — an estimated $191K sold.

PharVision Advisers first reported a position in PTEN in Q3 2025 and held it in 2 quarters. The position peaked at $191K in Q4 2025. 410 funds tracked by Wall St. Rank hold PTEN as of Q1 2026.

PharVision Advisers reported no remaining Patterson-UTI position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 31,193 Patterson-UTI shares in Q1 2026, an estimated $191K.
PharVision Advisers first reported a position in Patterson-UTI in Q3 2025 and held it in 2 quarters.
PharVision Advisers's Patterson-UTI position peaked at $191K in Q4 2025.
410 funds tracked by Wall St. Rank held Patterson-UTI as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.